The unique immunosuppressive activity of brequinar sodium.
Jaffee
B D
BD
Division of Inflammatory Diseases Research, Du Pont Merck Pharmaceutical Company, Wilmington, Delaware 19880-0400.
Jones
E A
EA
Loveless
S E
SE
Chen
S F
SF
D000818:Animals; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D001713:Biphenyl Compounds / Q000494:pharmacology*; D003877:Dermatitis, Contact / Q000276:immunology; D004139:Dinitrofluorobenzene; D000939:Epitopes / Q000276:immunology; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced / Q000276:immunology; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007959:Lymphocyte Culture Test, Mixed; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008954:Models, Biological; D012756:Sheep; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology; D011798:Quinaldines
D001713:Biphenyl Compounds; D004139:Dinitrofluorobenzene; D000939:Epitopes; D007166:Immunosuppressive Agents; C046943:brequinar; D011798:Quinaldines